T lymphocytes must regulate nutrient uptake to meet the metabolic demands of an immune response. Here we show that the intracellular supply of large neutral amino acids (LNAAs) in T cells was regulated by pathogens and the T cell antigen receptor (TCR). T cells responded to antigen by upregulating expression of many amino-acid transporters, but a single System L ('leucinepreferring system') transporter, Slc7a5, mediated uptake of LNAAs in activated T cells. Slc7a5-null T cells were unable to metabolically reprogram in response to antigen and did not undergo clonal expansion or effector differentiation. The metabolic catastrophe caused by loss of Slc7a5 reflected the requirement for sustained uptake of the LNAA leucine for activation of the serine-threonine kinase complex mTORC1 and for expression of the transcription factor c-Myc. Control of expression of the System L transporter by pathogens is thus a critical metabolic checkpoint for T cells.
T lymphocytes respond to antigen by proliferating and differentiating into effector subpopulations that mediate the adaptive immune response. Activated T cells must modulate their metabolic programs to match the metabolic demands of participating in an immune response. For example, activation of T cells results in much more protein synthesis, and such cells must accordingly increase their uptake of amino acids. Notably, amino acids are required not only for protein synthesis but also for other cellular processes such as glutaminolysis, a metabolic process in which glutamine is diverted into metabolic intermediates such as pyruvate and lactate 1, 2 . It is also important that T cells control the intracellular supply of leucine because leucine availability controls the activity of the serine-threonine kinase complex mTORC1 (refs. 3-6) . This kinase regulates the differentiation, memory and migratory ability of CD8 + cytotoxic T cells (CTLs) [7] [8] [9] [10] . It also promotes the differentiation of CD4 + cells of the T H 1 and T H 17 subsets of helper T cells while suppressing the differentiation of regulatory T cells that express the transcription factor Foxp3 (refs. 6, [11] [12] [13] . The mechanisms used by mTORC1 to control T cell differentiation are not fully understood, although it is known that this kinase complex is required for the glycolytic reprogramming that accompanies effector T cell differentiation 5, [14] [15] [16] .
The transport of leucine, a large neutral amino acid (LNAA), is mediated mainly by System L1 amino-acid transporters, which transport leucine and other hydrophobic LNAAs, or by System y + L aminoacid transporters, which transport cationic amino acids as well as LNAAs. These transporters are composed of a heterodimer of the heavy chain CD98 (Slc3a2) [17] [18] [19] plus the light chains Slc7a5, Slc7a8, Slc7a7 or Slc7a6 (ref. 20) . Deletion or mutation of the gene encoding CD98 results in early embryonic death 21, 22 , and selective deletion of CD98 has shown that this molecule is critical for the proliferative expansion of T cells and B cells 23, 24 . Moreover, mice with T cellspecific deficiency in CD98 can accept a fully major histocompatibility complex-mismatched cardiac allograft 25 . However, such studies have not provided information about the relevance of System L amino-acid transporters in lymphocytes because CD98 forms complexes not only with amino-acid transporters but also with integrins. Moreover, reconstitution experiments have shown that the integrin-binding domain of CD98 is important for lymphocyte proliferation, whereas the amino acid-transport function is dispensable for this. Hence, CD98 is proposed to regulate lymphocytes because it amplifies integrin signals and not because it forms complexes with light chains of aminoacid transporters 23, 24 .
The relevant LNAA transporters in T lymphocytes are thus not known, and indeed it is not known whether the transport of LNAAs is coupled to T cell activation. Evidence exists, however, showing that pharmacological blockade of System L transport function blocks T cell proliferation 5, 26 . Accordingly, the focus of our study here was to examine the dynamics and relevance of System L transport activity in immunologically activated T cells. We found that triggering via pathogens and T cell antigen receptors (TCRs) induced a much greater ability of T cells to transport LNAAs via System L transporters. Moreover, System L-mediated transport of leucine was essential for mTORC1 activity in T cells. System L transport activity in T cells required sustained activation of the immune response via the TCR or inflammatory cytokines such as interleukin 2 (IL-2). Transcriptional profiling of activated T cells identified Slc7a5 as a candidate for the A r t i c l e s TCR-regulated System L amino-acid transporter. Accordingly, we examined the consequences of the loss of Slc7a5 for T cell development and peripheral T cell function. We found that Slc7a5 was the main LNAA transporter in T cells activated via the antigen receptor. Moreover, loss of Slc7a5 prevented the proliferation and differentiation of CD4 + T cells and CD8 + T cells, although the ability of CD4 + T cells to differentiate into regulatory T cells was unimpaired. Unexpectedly, Slc7a5-null T cells activated via the antigen receptor had complex metabolic defects beyond a simple loss of LNAA uptake. Slc7a5-null T cells triggered via the TCR did not increase their uptake of glutamine, transferrin and glucose and did not undergo a metabolic switch to glycolysis after TCR stimulation. The catastrophic effect of the loss of Slc7a5 was explained in part by the requirement for sustained leucine uptake for mTORC1 activity. However, it also reflected the finding that Slc7a5-null T cells responded to activation only by increasing the abundance of mRNA encoding the transcription factor c-Myc and key nutrient transporters but not by increasing the abundance of the proteins themselves. Our data demonstrate that aminoacid transport regulated by TCRs and cytokines controls mTORC1 activity in T cells. Moreover, the regulated expression of Slc7a5 is a key event for the metabolic reprogramming of T cells.
RESULTS
Antigen and IL-2 regulate System L amino-acid transport Naive CD8 + T cells did not effectively take up 3 H-labeled phenylalanine, an LNAA that is transported by System L amino-acid transporters ( Fig. 1a) . However, triggering of CD8 + T cells via the TCR with cognate peptide induced a substantial increase in phenylalanine transport ( Fig. 1a) . Effector CD8 + T cells from mice immunized with Listeria monocytogenes also had more phenylalanine transport than did naive T cells ( Fig. 1b) . CD8 + T cells primed via the TCR and cultured in IL-2 clonally expand and differentiate into CTLs. CTLs cultured in IL-2 had enhanced phenylalanine uptake, and removal of IL-2 or exposure to limiting concentrations of IL-2 resulted in less phenylalanine uptake by CTLs ( Fig. 1c ). Uptake of [ 3 H]phenylalanine by CTLs was diminished by competition with unlabeled leucine but not by competition with basic amino acids such as lysine or the acidic amino acid aspartic acid ( Fig. 1d) . Moreover, treatment of CTLs with BCH, an inhibitor of System L amino-acid transporters, blocked the influx of phenylalanine into CTLs, whereas treatment with MeAIB, an inhibitor of amino-acid transport by System A, did not ( Fig. 1d) . Thus, activated effector T cells increased their activity of System L amino-acid transporters.
Depriving CTLs of amino acids resulted in rapid inactivation of mTORC1, as judged by loss of phosphorylation of the mTORC1 substrate sequence (Thr389) in p70 S6 kinase 1 (p70S6K) and of the p70S6K substrate sequences (Ser235 and Ser236) in the S6 ribosomal subunit ( Fig. 2a,b) . The activity of mTORC1 was rapidly restored after we added exogenous leucine back to the cells (Fig. 2b) . Furthermore, when we added replete medium lacking glutamine alone back after depletion of amino acids, S6 phosphorylation was recovered, whereas when we used medium lacking leucine, S6 phosphorylation was not restored ( Fig. 2c ). CTLs treated with BCH, the selective inhibitor of System L transport, also rapidly lost mTORC1 activity, similar to their response to treatment with the mTORC1 inhibitor rapamycin ( Fig. 2d) . T cells deprived of leucine alone also did not sustain mTORC1 activity ( Fig. 2e ). Published studies have indicated that glutamine availability also regulates mTORC1 activity. The molecular basis for this glutamine sensitivity is proposed to be the actions of Slc7a5-Slc3a2 operating as a bidirectional transporter regulating the simultaneous efflux of glutamine and influx of leucine 27 . Removal of glutamine for 1 h also resulted in loss of mTORC1 activity ( Fig. 2e) , whereas the addition of glutamine alone to amino acid-deprived CTLs without the presence of leucine did not restore mTORC1 activity ( Fig. 2b,c) . Collectively these data showed that the intracellular supply of the branched-chain amino acid leucine via System L transporters was important for sustaining mTORC1 activity in T cells.
Slc7a5, the System L transporter in activated T cells
To identify candidate System L transporters in T cells, we examined Affymetrix microarray data of naive P14 T cells (which have transgenic expression of a TCR specific for glycoprotein gp33 of lymphocytic choriomeningitis virus) and P14 T cells activated via the antigen receptor 28 . These data showed that the nutrient transporter whose expression underwent the most induction via the TCR was Slc7a5 (LAT1; Fig. 3a ). Triggering via the TCR also induced a greater abundance of mRNA encoding CD98 (Slc3a2), the heavychain subunit of System L transporters. Quantitative PCR analysis confirmed that the abundance of Slc7a5 mRNA was greater in T cells activated for 4 h or 20 h with antigen ( Fig. 3b) . We detected Slc7a5 protein only in T cells activated for 20 h (Fig. 3b) . We detected surface expression of CD98 on T cells activated for 4 h with antigen, yet T cells activated for 20 h had higher CD98 expression ( Fig. 3b) . The uptake of [ 3 H]phenylalanine was also greater in cells stimulated for 20 h via the TCR than in unstimulated cells or cells stimulated for 4 h (Fig. 1a) . CTLs cultured in IL-2 had abundant Slc7a5 mRNA and Slc7a5 protein, but this was dependent on sustained exposure to this cytokine ( Fig. 3c) . Transcriptional profiling has also indicated that OT-I effector CD8 + T cells (which have transgenic expression of an ovalbumin (OVA)-specific TCR) isolated from L. monocytogenesinfected mice selectively upregulate Slc7a5 expression (data assembled by the Immunological Genome Project consortium) 29 . A r t i c l e s Thus, we found a strong correlation between the expression of Slc7a5 and activity of System L transporters in peripheral T cells. We next addressed how TCR signaling induced Slc7a5 expression. TCR-driven uptake of glucose and glutamine is regulated by the mitogen-activated protein kinases Erk1 and Erk2 (Erk1-2) and mTORC1 (refs. 2,14,16) . However, PD184352, which prevents activation of Erk1-2, and rapamycin, which inhibits the mTORC1 complex, had no effect on the ability of triggering via the TCR to induce System L transport activity ( Fig. 3d) . Triggering of the TCR complex is known to lead to an increase in intracellular calcium and sustained activation of the calcium-regulated phosphatase calcineurin. Cyclosporin A (CsA), which inhibits calcium-calcineurin signaling pathways, abrogated TCR-induced System L activity ( Fig. 3d) . CsA prevents the production of the cytokine IL-2 by T cells activated by the immune system. Nevertheless, the addition of exogenous IL-2 to CsA-treated T cells activated via the TCR did not restore System L activity ( Fig. 3e) . CsA also prevented the induction, via the TCR, of Slc7a5 mRNA expression ( Fig. 3f) . These results indicated that calcineurin-regulated signaling pathways mediated the control of Slc7a5 expression by the TCR.
Generation of Slc7a5-null T cells
Systemic deletion of Slc7a5 caused embryonic death (data not shown). However, mice with deletion of single functional Slc7a5 allele were born at the expected Mendelian frequency and had normal peripheral lymphocyte subpopulations (data not shown). T cells haploinsufficient for Slc7a5 underwent normal blastogenesis and proliferation in response to triggering via the TCR and IL-2 (data not shown). They also had lower expression of Slc7a5 mRNA and Slc7a5 protein and 50% lower System L transporter activity than that of their wild-type littermates while maintaining normal glutamine uptake ( Supplementary Fig. 1 ). To further probe the importance of Slc7a5 in T cells, we generated mice with loxP-flanked Slc7a5 alleles that also expressed Cre recombinase from the promoter of the gene encoding CD4 (Slc7a5 fl/fl CD4-Cre mice) to delete Slc7a5 in CD4 + CD8 + double-positive thymocytes and all subsequent T cell populations. We confirmed deletion of Slc7a5 alleles in Slc7a5 fl/fl CD4-Cre T cells by genomic PCR analysis ( Fig. 4a) . Slc7a5 fl/fl CD4-Cre mice had normal numbers and frequencies of conventional αβ T cells and natural killer T cells in the thymus (Fig. 4b) . Slc7a5 forms a heterodimer with CD98, and one question we sought to address was the effect of the deletion of Slc7a5 on CD98 expression. Slc7a5 fl/fl CD4-Cre CD4 + CD8 + (double-positive) and CD4 + or CD8 + (single-positive) thymocytes expressed approximately 50% less CD98 than did wildtype cells (Fig. 4c) , and peripheral T cells from Slc7a5 fl/fl CD4-Cre mice also had approximately 50% less CD98 at the membrane than did cells from their Slc7a5 fl/fl littermates (Fig. 4d) . Slc7a5 fl/fl CD4-Cre mice also had normal numbers and frequencies of naive CD4 + and CD8 + T cell subsets in the spleen and lymph nodes and a normal frequency of Foxp3 + regulatory T cells (Fig. 4e) . We also used a Vav-Cre transgene to delete Slc7a5 in hematopoietic progenitors in the bone marrow 30 . Slc7a5 fl/fl Vav-Cre mice had normal thymocyte numbers and a normal distribution of CD4 − CD8 − , CD4 + CD8 + and CD4 + or CD8 + subsets. They also had normal numbers and frequencies of peripheral T lymphocyte subpopulations, B lymphocytes and natural killer cells (Supplementary Fig. 2) .
The phenotype of Slc7a5 fl/fl CD4-Cre mice indicated that Slc7a5 was not required for T cell selection in the thymus or for homeostasis of the naive T cell pool. We confirmed that conclusion when we backcrossed Slc7a5 fl/fl CD4-Cre mice onto OT-I mice that express a V α 2V β 5 TCR specific for the OVA-derived peptide SIINFEKL (to generate OT-I Slc7a5 fl/fl CD4-Cre mice). Thymocyte development and peripheral T cell numbers in OT-I Slc7a5 fl/fl CD4-Cre mice were normal (data not shown). T cells that developed in Slc7a5 fl/fl CD4-Cre had undetectable expression of Slc7a5 protein (Fig. 4f) . Notably, analysis of phenylalanine uptake showed that OT-I Slc7a5 fl/fl CD4-Cre T cells activated via the TCR had no detectable System L transporter activity (Fig. 4g) .
Defective immune responses of Slc7a5 fl/fl CD4-Cre T cells
We next explored the response of Slc7a5 fl/fl CD4-Cre T cells to immunological activation. Slc7a5 fl/fl CD4-Cre CD4 + T cells did not respond to ligation of the antigen receptor and the appropriate polarizing cytokines to effectively produce T H 1 or T H 17 cells (Fig. 5a) . Slc7a5 fl/fl CD4-Cre CD8 + T cells also had a substantial defect in their ability to respond to cognate antigen and IL-2 to produce cytotoxic effector cells (Fig. 5a) . However, Slc7a5 fl/fl CD4-Cre CD4 + T cells responded normally to transforming growth factor-β (TGF-β) and IL-2 to generate Foxp3 + induced regulatory T cells (Fig. 5a) .
To explore the importance of Slc7a5 for T cell-mediated immune responses in vivo, we investigated the ability of Slc7a5 fl/fl CD4-Cre mice to generate a T cell-dependent antibody response to the model antigen nitrophenyl linked to OVA (NP-OVA). T cell expression of Slc7a5 was not required for mice to respond to immunization with NP-OVA by making antibodies of the immunoglobulin M (IgM) class (Fig. 5b) . However, affinity maturation of antibody production and the production of high-affinity NP-specific IgG1 responses was considerably impaired in Slc7a5 fl/fl CD4-Cre mice.
The generation of a high-affinity antibody response requires that follicular helper T cells and B cells work together in germinal centers. The provision of T cell help to B cells was thus dependent on T cell expression of Slc7a5.
To explore the role of Slc7a5 in CD8 + T cell function in vivo, we adoptively transferred OT-I and OT-I Slc7a5 fl/fl CD4-Cre CD8 + T cells into naive recipient mice and monitored their responses to immunization with cognate antigen and lipopolysaccharide. OT-I Slc7a5 fl/fl CD4-Cre T cells had a substantial defect in their ability to produce effector CD8 + T cells in vivo (Fig. 5c) . Fewer OT-I Slc7a5 fl/fl CD4-Cre T cells than OT-I T cells were present in the spleens of immunized mice at day 7, and the OT-I Slc7a5 fl/fl CD4-Cre T cells were CD62L hi , in contrast to the CD62L lo phenotype of their OT-I counterparts (Fig. 5c) . (Fig. 5d,e) .
We also examined the importance of Slc7a5 expression for CD8 + T cells in vitro. OT-I Slc7a5 fl/fl CD4-Cre CD8 + T cells responded to cognate antigen in vitro with higher expression of CD25, CD69 and CD44 (Fig. 6a) . They were also able to secrete normal amounts of IL-2 and produced interferon-γ, although at much lower concentrations than those of their OT-I counterparts (Fig. 6b) . Thus, Slc7a5 was not required for the initial events of T cell activation. Flow cytometry analyzing forward and side scatter showed that OT-I Slc7a5 fl/fl CD4-Cre T cells did not undergo normal blastogenesis (Fig. 6c) . Hence, OT-I Slc7a5 fl/fl CD4-Cre T cells activated via the TCR were much smaller than were OT-I T lymphoblasts. In this context, TCR-mediated activation of OT-I T cells induced enhanced ribosomal biogenesis, as assessed by high expression of S6 ribosomal subunits in T cells activated via the TCR (Fig. 6d) . In contrast, OT-I Slc7a5 fl/fl CD4-Cre T cells did not upregulate S6 protein (Fig. 6d) . Furthermore, OT−I Slc7a5 fl/fl CD4-Cre T cells did not proliferate in response to TCR triggering in vitro. OT-I CD8 + T cells underwent multiple cell divisions in response to the OT-I TCR ligand SIINFEKL, but OT-I Slc7a5 fl/fl CD4-Cre CD8 + T cells did not (Fig. 6c) . We also assessed the ability of Slc7a5-null CD4 + and CD8 + T cells to undergo lymphopenia-induced proliferation in vivo. In these experiments, we adoptively transferred Slc7a5 +/+ and Slc7a5 fl/fl CD4-Cre T cells at a ratio of 1:1 into lymphopenic recipient mice (deficient in recombination-activating gene 2). After 14 d, the recovery of Slc7a5 +/+ and Slc7a5 fl/fl CD4-Cre T cells from recipient spleens showed that Slc7a5 was essential in allowing both CD4 + T cells and CD8 + T cells to undergo proliferative expansion in a lymphopenic environment (Fig. 6e) . Slc7a5 was thus essential for the adaptive immune responses mediated by CD4 + T cells and CD8 + T cells.
Slc7a5 is essential for T cell metabolic reprogramming
Why were Slc7a5-null polyclonal and OT-I T cells unable to differentiate or proliferate? That finding could not have been solely due to loss of mTORC1 activity caused by lack of leucine uptake because the phenotype of Slc7a5-null T cells was much more deleterious than the phenotypes caused by loss of mTORC1 activity; for example, inhibition of mTOR does not prevent T cell clonal expansion 9, 14 . In this context, the cell-growth and blastogenic defects of the Slc7a5-null T cells prompted analysis of the effect of the deletion of Slc7a5 on the ability of T cells to metabolically reprogram in response to immunological activation. Published studies have shown that metabolism of glucose and glutamine in T cells is regulated by the transcription factor c-Myc, which acts to control expression of transporters of glucose and glutamine 16 . The c-Myc protein has a very short halflife 31, 32 , and we hypothesized that expression of c-Myc protein might be very sensitive to loss of a key amino-acid transporter. Slc7a5 fl/fl CD4-Cre cells responded to immunological activation with higher expression of Myc mRNA but no upregulation of the expression of c-Myc protein (Fig. 7a) . Notably, this effect of the lack of Slc7a5 on c-Myc expression was not explained by the role of amino-acid uptake in controlling mTORC1 activity. Hence, treatment of OT-I T cells with rapamycin inhibited mTORC1 activity but did not prevent the TCRmediated increase in expression of c-Myc protein (Fig. 7b) .
Expression of c-Myc is required for the glycolytic switch and increase in glutaminolysis that accompanies T cell activation 16 . In this context, OT-I Slc7a5 fl/fl CD4-Cre T cells did not increase expression of the glucose transporter Glut1 after stimulation via the TCR (Fig. 7c) . OT-I Slc7a5 fl/fl CD4-Cre T cells triggered via the TCR also had significantly less glucose uptake and lactate output than did their OT-I counterparts (Fig. 7d) . Furthermore, OT-I Slc7a5 fl/fl CD4-Cre T cells also did not increase their uptake of glutamine or arginine in response to activation (Fig. 7e) and did not express the transferrin receptor CD71 (Fig. 7f) . The lack of expression of Glut1 and CD71 protein by antigen-activated OT-I Slc7a5 fl/fl CD4-Cre T cells was not a result of their inability of these cells to increase their abundance of A r t i c l e s mRNA encoding these proteins. There was thus no detectable difference between OT-I and OT-I Slc7a5 fl/fl CD4-Cre T cells activated via the TCR in the abundance of mRNA encoding CD71 and Glut1; the only difference was in their expression of CD71 and Glut1 protein ( Fig. 7c,f) . The expression of Slc7a5 was thus required for T cells to sustain c-Myc expression and to sustain expression of proteins encoding key nutrient transporters.
DISCUSSION
Here we have shown that System L amino-acid transport activity in peripheral T lymphocytes was linked to the immunological activation of these cells by pathogens. Triggering of the TCR resulted in a much greater ability of T cells to transport LNAAs across their plasma membranes. Moreover, System L amino-acid transport activity was not autonomous in antigen-primed T cells but required sustained immunological activation via the TCR or inflammatory cytokines such as IL-2. The ability of the TCR to control System L transporter activity indicates that mechanisms have evolved to link T cell responses to pathogens with the ability of T cells to control intracellular pools of amino acids. In this context, it was noteworthy that the ability of TCR triggering to induce System L amino-acid transport activity in T cells was prevented by inhibition of calcineurinmediated signaling pathways by CsA, a powerful immunosuppressive drug. These data afford some insight that part of the mechanism of the action of CsA may be to prevent TCR-induced reprogramming of amino-acid metabolism. At least four genes encoding System L1 and System y + L transporters have been described 20 , but it is notable that triggering via the TCR resulted in higher expression of the System L transporter Slc7a5 and that this single transporter was responsible for mediating uptake of LNAAs in immunologically activated T cells. Slc7a5 is thus the dominant LNAA transporter in such cells, and no redundancy exists between other System L1 or System y + L transporters. We found that Slc7a5 was not apparently needed for T cell development in the thymus. T cell progenitors in the thymus proliferate rapidly after TCR β-chain selection; this is a metabolically demanding process in which expression of LNAA transporters should be essential. Our finding of no defects in thymic development in Slc7a5 fl/fl CD4-Cre mice could reflect the fact that Cre expressed from this transgene deleted Slc7a5 after the cells had passed the biosynthetically demanding stage of pre-T cell proliferation. However, use of a Vav-Cre transgene to delete Slc7a5 in hematopoietic progenitor cells in the bone marrow 30 showed that Slc7a5 fl/fl Vav-Cre mice also had no defects in thymus development. There must therefore be other LNAA transporters that can substitute for Slc7a5 in progenitors of T cells. In this context, transcriptional profiling has indicated that progenitors of T cells have abundant expression of Slc7a6 (y + LAT2) and Slc7a5 (LAT1) 29 . The dependence of T cells on Slc7a5 was thus restricted to effector T cells undergoing proliferative expansion and differentiation in response to pathogens. Slc7a5 was not required for the maintenance of naive T cells. It is also noteworthy that Foxp3-expressing natural and induced regulatory T cells were not dependent on Slc7a5 expression.
Why would effector T cells be so dependent on Slc7a5? We found that System L-mediated intracellular transport of leucine was essential for mTORC1 activity in activated T cells. The inability of Slc7a5null T cells to sustain mTORC1 activity would thus cause defects in the differentiation of CD4 + T cells and CD8 + T cells 6, 13, 33 . The ability of mTORC1 to sense leucine uptake allows this kinase to modulate cellular responses to nutrient availability. Our data afford the insight that the TCR has assumed control of this evolutionarily conserved pathway and controls mTORC1 activity by controlling the expression of leucine transporters. The rate of intracellular leucine uptake in T cells is thus not determined by the extracellular leucine concentration but by control of leucine transporter expression by the TCR. How does leucine control mTORC1 activity in mammalian cells? This process is not fully understood, although it has been proposed that the sensing of amino acids for mTORC1 activity in mammalian cells is initiated in lysosomes and involves amino acid-dependent activation of the guanine nucleotide-exchange activity of the Ragulator complex 34 . This results in the accumulation of active GTP-bound RagA GTPases, which then recruit mTORC1 to the lysosomal surface 34 , where it interacts with the small GTPase Rheb, a potent stimulator of mTORC1 kinase activity in T cells 13 . One candidate for the direct amino-acid sensor involved in regulating the activity of the Rag GTPases is leucyl-tRNA synthetase 35, 36 .
The role of leucine in controlling mTORC1 activity does not fully explain the functional defects of Slc7a5-null T cells. For example, deletion of Slc7a5 prevented T cell clonal expansion, but inhibition of mTORC1 by rapamycin did not. However, there were selective and critical protein-synthesis defects in activated Slc7a5-null T cells that had a catastrophic effect on the ability of Slc7a5-null T cells to reprogram metabolism. Immunologically activated Slc7a5-null T cells did not increase glucose transport because they increased expression only of mRNA encoding the glucose transporter Glut1 but were unable to express Glut1 protein. Slc7a5-null T cells did not express the transferrin receptor CD71 and they also did not increase glutamine uptake in response to TCR triggering. In this context, the Slc7a5-null T cells are a close phenocopy of c-Myc-null T cells in their inability to upregulate metabolism of glucose and glutamine in response to immunological activation 16 . The explanation for this similarity is that Slc7a5-null T cells are effectively c-Myc null. They can respond to immunological activation to increase expression of mRNA encoding c-Myc but they do not express c-Myc protein. Accordingly, Slc7a5-null T cells are unable to upregulate the 'metabolic machinery' needed to permit the proliferation and differentiation of T cells. We emphasize that Slc7a5-null T cells did not have global defects in protein synthesis and were able to respond to triggering via the TCR by upregulating expression of CD25 (the IL-2 receptor), CD69 and CD44. Slc7a5-null T cells activated via the TCR also secreted normal amounts of IL-2 and reasonable, albeit lower, amounts of interferon-γ. Why is Slc7a5 needed for c-Myc expression but not for the expression of many other proteins? One insight into this is that c-Myc has very short half-life and needs to be constantly resynthesized. For example, the estimated half life of c-Myc is 15 min, whereas the half life of CD25 is >18 h (refs. 31, 37) . Proteins with a short half-life that need to be continually resynthesized will be much more dependent on sustained uptake of amino acids.
In summary, our study has emphasized the finding that inducing LNAA transport through controlling expression of Slc7a5 was a chief function of the TCR. The directed transport of leucine through System L transporters controlled mTORC1 activity in T cells and was also needed to sustain c-Myc expression in activated T cells. The failure of TCR-activated Slc7a5-null T cells to express c-Myc cannot be explained by the loss of mTORC1 signaling, as inhibition of mTORC1 by rapamycin does not ablate c-Myc expression 14 . However, the inability of immunologically activated Slc7a5-null T cells to sustain c-Myc expression caused many metabolic defects. The loss of c-Myc and mTORC1 activity was thus sufficient to explain the phenotype of Slc7a5-null T cells, although we do not exclude the possibility that Slc7a5 expression may also control the expression of other critical signaling molecules. Nevertheless, our data have shown that the control of Slc7a5 expression and amino-acid uptake by antigen receptors and pathogens is a critical switch for the metabolic reprogramming that allows immunologically activated T cells to mediate adaptive immune responses.
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